WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/04/15 | $18,000,000 | Series A |
Kagoshima Shinsangyo Sosei Investment RA Capital SNBL | undisclosed |
| 08/19/15 | $66,000,000 | Series B |
Clough Capital Partners Cormorant Asset Management Fidelity Investments Foresite Capital Jennison Associates Kagoshima Shinsangyo Sosei Investment New Leaf Venture Partners RA Capital Redmile Group | undisclosed |
